Familial Chylomicronemia Syndrome Clinical Trials

27 clinical trials for Familial Chylomicronemia Syndrome across international registries, including 4 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Study of Olezarsen for the Treatment of Familial Chylomicronemia Syndrome (FCS) in Pediatric Participants — RECRUITING · PHASE3
• CS-121 APOC3 Base Editing in FCS — RECRUITING · PHASE1
• AN OPEN-LABEL SAFETY STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) PREVIOUSLY TREATED WITH VOLANESORSEN (ISIS 304801) — RECRUITING
• AN OPEN-LABEL EXTENSION STUDY OF AKCEA-APOCIII-LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) — RECRUITING
• A randomized, double-blind, placebo controlled study to assess efficacy, safety and tolerability of LCQ908 in subjects with Familial Chylomicronemia Syndrome — COMPLETED · PHASE3
• ISIS 678354-CS13: An Open-Label Extension Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients with Familial Chylomicronemia Syndrome (FCS) — TERMINATED · PHASE3
• A Phase 3 Study to Evaluate the Efficacy and Safety of ARO-APOC3 in Adults with Familial Chylomicronemia Syndrome — OTHER · PHASE3
• ISIS 678354-CS7: An Open-Label Study of AKCEA-APOCIII-LRX Administered Subcutaneously to Patients With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen (ISIS 304801) — TERMINATED · PHASE3
• A Phase 3 Study of ARO-APOC3 / VSA001 / SAR449124 (Plozasiran) in Chinese Adults With Familial Chylomicronemia Syndrome — COMPLETED · PHASE3
• Study of RN0361in Adult Healthy Subjects and Adult Hypertriglyceridemic Subjects — ACTIVE_NOT_RECRUITING · PHASE1
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) in Participants With Familial Chylomicronemia Syndrome (FCS) — ACTIVE_NOT_RECRUITING · PHASE3
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRX) Administered to Adults With Familial Chylomicronemia Syndrome (FCS) Previously Treated With Volanesorsen — ACTIVE_NOT_RECRUITING · PHASE3
• AN OPEN-LABEL STUDY OF OLEZARSEN (ISIS 678354) ADMINISTERED SUBCUTANEOUSLY TO PEDIATRIC PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) — NOT_YET_RECRUITING
• A Study of Olezarsen (Formerly Known as AKCEA-APOCIII-LRx) Administered to Patients With Familial Chylomicronemia Syndrome (FCS) — COMPLETED · PHASE3
• Olezarsen Early Access Program for Patients With Familial Chylomicronemia Syndrome (FCS) — OTHER
• The APPROACH Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Patients With Familial Chylomicronemia Syndrome — COMPLETED · PHASE3
• PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ARO-APOC3 IN ADULTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME — COMPLETED · PHASE3
• The Approach Open Label Study: A Study of Volanesorsen (Formerly IONIS-APOCIIIRx) in Participants With Familial Chylomicronemia Syndrome — COMPLETED · PHASE3
• Phase 2 Study of AKCEA-ANGPTL3-LRx (ISIS 703802) in Participants With Familial Chylomicronemia Syndrome (FCS) — COMPLETED · PHASE2
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF AKCEA APOCIII LRX ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) — COMPLETED · PHASE3
• A PHASE 1 SINGLE AND MULTIPLE DOSE-ESCALATING STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMIC EFFECTS OF ARO-APOC3 IN ADULT HEALTHY VOLUNTEERS AS WELL AS IN SEVERELY HYPERTRIGLYCERIDEMIC PATIENTS AND PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME. — COMPLETED · PHASE1
• InFocus France Epidemiological Study of Health Burden in Major Hypertriglyceridemia — COMPLETED
• Medical Complications in Familial and Multifactorial Chylomicronaemia Syndromes — COMPLETED
• A PHASE 2 OPEN-LABEL STUDY TO ASSESS THE PHARMACODYNAMICS, PHARMACOKINETICS, SAFETY AND TOLERABILITY OF AKCEA-ANGPTL3-LRX (ISIS 703802) ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) — COMPLETED · PHASE2
• AN OPEN-LABEL EXTENSION STUDY OF VOLANESORSEN ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA (FCS) — COMPLETED
• A Randomized, Double-blind, Placebo Controlled Study to Assess Efficacy, Safety and Tolerability of LCQ908 in Subjects With Familial Chylomicronemia Syndrome — COMPLETED · PHASE3
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 STUDY OF ISIS 304801 ADMINISTERED SUBCUTANEOUSLY TO PATIENTS WITH FAMILIAL CHYLOMICRONEMIA SYNDROME (FCS) — COMPLETED · PHASE3

Refine this search